A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis.

drug protocol number
EFC17504
drug sponsor
Sanofi / Arab Med
drug study
Frexalimab (SAR441344)
drug trial site
King Saud University Medical City (Riyadh)
drug status
Ongoing
drug phase